跳至主要内容
临床试验/NCT02248207
NCT02248207已完成不适用

Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice

Boehringer Ingelheim0 个研究点目标入组 1,293 人开始时间: 2003年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,293
主要终点
Global Assessment of efficacy by investigator on a 4-point scale

研究概览

简要总结

Study to obtain information about the co-operation of the different physician-colleagues in the treatment of patients with Parkinson's disease, both in private practices and clinics and about the primary treatment strategies in the pharmacotherapy of Parkinson's disease and to collect data on the tolerability of Sifrol® in ambulatory patients suffering from Parkinson's disease under routing conditions

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with Parkinson's disease who present to the specialist neurologist practice for the first time without or with referral and who are planned to receive or either be switched to Sifrol or continue the previously prescribed therapy with Sifrol® can be included in this observational study

排除标准

  • Neurologists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®

研究组 & 干预措施

Parkinson Disease patients

干预措施: Pramipexole (Drug)

结局指标

主要结局

Global Assessment of efficacy by investigator on a 4-point scale

时间窗: after 8 weeks

Change from Baseline in actual Parkinson symptoms

时间窗: Baseline, after 8 weeks

Global Assessment of tolerability by investigator on a 4-point scale

时间窗: after 8 weeks

次要结局

  • Number of patients with adverse drug reactions(up to 8 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验